



Human induced pluripotent stem cell-derived cardiomyocyte patches ameliorate right ventricular function in a rat pressure-overloaded right ventricle model

Takuji Watanabe¹ · Takuji Kawamura¹ · Akima Harada¹ · Masaki Taira¹ · Daisuke Yoshioka¹ · Kazuo Shimamura¹ · Tadashi Watabe² · Eku Shimosegawa² · Takayoshi Ueno¹ · Shigeru Miyagawa¹

Received: 16 February 2024 / Accepted: 21 October 2024 / Published online: 6 December 2024
© The Author(s) 2024

Abstract

Right ventricular (RV) failure following surgical repair of congenital heart disease affects survival. Human induced pluripotent stem cell-derived cardiomyocyte (hiPS-CM) sheet transplantation ameliorated left ventricular dysfunction in preclinical studies, indicating its efficacy in RV failure in congenital heart disease. This study aimed to evaluate whether hiPS-CMs could improve RV function in rats with pressure-overloaded RV failure. F344/NJcl-rnu/rnu rats underwent pulmonary artery banding (PAB) via left thoracotomy. Four weeks after PAB, hiPS-CM patch transplantation to the RV was performed in the hiPS-CM group (n = 33), and a sham operation was performed in the sham group (n = 18). We evaluated cardiac catheterization, positron emission tomography data, and pathological results 8 weeks following PAB. RV end-diastolic pressure, the time constant of isovolumic relaxation, and end-diastolic pressure–volume relation were significantly ameliorated in the hiPS-CM group compared with in the sham group. Picrosirius red staining revealed that anti-fibrotic effects were significantly higher in the hiPS-CM group than in the sham group. Von Willebrand factor staining revealed significantly higher myocardial capillary vascular density in the hiPS-CM group than in the sham group. hiPS-CMs were detected in the epicardium 4 weeks after hiPS-CM sheet transplantation. The angiogenic gene expression in the myocardium was significantly higher in the hiPS-CM group than in the sham group. Overall, in rats with pressure-overloaded RV failure, hiPS-CM patch transplantation could improve diastolic function, suppress ventricular fibrosis, and increase capillary density, suggesting that it is a promising treatment for RV failure.

Keywords RV failure · Congenital heart disease · hiPS-CM transplantation · Pressure-overloaded RV failure · Cardiomyocyte patch

Introduction

Recent advancements in diagnostics, surgical techniques, and perioperative management have increased congenital heart disease (CHD) survival rates [1]. However, intracardiac repair often causes pressure-overloaded right ventricles (RVs) [2–4], which can lead to RV failure, contributing to mortality and morbidity. There are no effective therapies for RV failure except heart transplantation [5]. RV dysfunction in CHD is attributed to relative RV ischemia from chronic overloading and fibrosis [6, 7]; novel therapies must be established.

Recently, regenerative therapy using skeletal myoblasts [8] and induced pluripotent stem cell-derived

✉ Shigeru Miyagawa
miya-p@surg1.med.osaka-u.ac.jp

Takuji Watanabe
watanabe.takuji.med@osaka-u.ac.jp

¹ Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2, Yamada-Oka, Suita, Osaka 565-0871, Japan

² Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan

cardiomyocytes (iPS-CMs) [9] has garnered attention to treat heart failure. We previously prepared cell sheets using temperature-responsive culture dishes [10, 11], developed a mass iPS-CM culture system, and reported the effectiveness of human iPS-CM (hiPS-CM) sheets in porcine ischemic cardiomyopathy [12].

The proposed mechanisms of the iPS-CM patch involve paracrine effects induced via angiogenic and antifibrotic factors. iPS-CM patch transplantation, with angiogenic and fibrosis-suppressing effects, may be effective for RV insufficiency. We herein hypothesized that hiPS-CMs would suppress or improve RV dysfunction caused by pressure overload by promoting angiogenesis and suppressing myocardial fibrosis. This study investigated whether hiPS-CM patches could improve RV function in RV pressure-overloaded rats.

Materials and methods

Study design

In this study, we evaluated the efficacy of hiPS-CM patches using a rat model of RV pressure overload. RV function was evaluated using positron emission tomography at 3 weeks and cardiac catheterization at 4 weeks following hiPS-CM patch transplantation or sham surgery; assessment of the transcript-level expression of proangiogenic cytokines in the RV myocardium was performed at 2 and 4 weeks following hiPS-CM patch transplantation and 4 weeks following sham surgery; and histological analysis was performed at 4 weeks following hiPS-CM patch transplantation or sham surgery (Fig. 1).

Ethical approval

The experimental protocols were approved by the Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine (reference number 01–059-000). Institutional guidelines for the care and use of laboratory animals have been observed.

Chronic pressure-overloaded RV model

Chronic RV pressure overload was induced in 7–9 week-old male athymic nude rats (F344/NJcl-rnu/rnu; CLEA Japan, Tokyo, Japan) by permanently banding the main pulmonary artery (PA). Rats were anesthetized by isoflurane (2–3%, O₂ carrier) inhalation, intubated, and placed on a volume-controlled respirator (2 mL, 60 cycles/min). The PA was dissected from the aorta through the fourth left intercostal space, and a 19-G needle was placed alongside the PA [13, 14]. Next, 3–0 polyester sutures were tied firmly around the needle and PA. The needle was removed to produce a fixed PA constriction proportional to the needle diameter (outer diameter: 1.1 mm).

hiPS-CM patch transplantation

Four weeks after pulmonary artery banding, a second operation was performed through the fifth left intercostal space under general anesthesia. A prepared hiPS-CM patch (4×10^6 cells/patch) was transplanted onto the anterior RV wall (hiPS-CM group, $n = 33$), or sham surgery was conducted (sham group, $n = 18$) (Supplementary Materials and Methods, Fig. S1). The hiPS-CM patch was fixed to the RV wall using Beriplast P (CSL Behring, King of Prussia, Pennsylvania, USA), and the pericardium was closed to prevent patch migration/adhesion to the chest wall. A control group of age-matched rats ($n = 10$) that did not undergo surgical intervention was included (Fig. 1).

Histology

Myocyte size was determined using point-to-point perpendicular lines across the cross-sectional area of the cell through the nucleus (results are expressed as the average diameter of 10 myocytes that were randomly selected from five fields of each ventricle). The fibrotic area was calculated




Fig. 1 Study protocol. PAB Pulmonary artery banding; hiPS-CM Human induced pluripotent stem cell-derived cardiomyocyte, PCR Polymerase chain reaction, PET/CT Positron emission tomography/computed tomography

as the percentage of the myocardial area using Metamorph (Molecular Devices LLC, San Jose, CA, USA). Vessel density was quantified as the number of von Willebrand factor (vWF)-positive vessels per mm^2 . Data were obtained from five individual views of each heart.

Statistical analyses

Statistical analyses were performed using JMP Pro (17.1.0; SAS Institute, Cary, NC, USA). Data are expressed as the mean \pm standard deviation. Continuous variables were examined using Welch's *t*-test, and normality was tested using the Shapiro–Wilk test. One-way analysis of variance was used to compare values among groups; when significant, group differences were compared using Tukey's honest significance difference test. Relationships between capillary density and the percentage of myocardial fibrosis were assessed using linear regression and Pearson's correlation. All *P*-values were two-tailed, and *P*-values < 0.05 were considered statistically significant.

Results

hiPS-CM patch transplantation improved RV function

During cardiac catheterization, steady-state end-diastolic pressure (sham vs. hiPS-CM: 9.9 ± 3.5 vs. 5.8 ± 1.7 mmHg; $P < 0.001$) and tau (sham vs. hiPS-CM: 19.6 ± 5.9 vs. 15.3 ± 2.5 ms; $P = 0.011$), which are indicators of diastolic function, were significantly lower in the hiPS-CM group (Fig. 2b). The dP/dt max (sham vs. hiPS-CM: 2860 ± 981 vs. 3647 ± 1162 mmHg/s; $P = 0.047$) and dP/dt min (sham vs. hiPS-CM: -1973 ± 412 vs. -2508 ± 738 mmHg/s; $P = 0.021$), which are indicators of systolic and diastolic function, respectively, were significantly different between the groups (Fig. 2b). Stroke work (sham vs. hiPS-CM: 2.77 ± 1.51 vs. 6.29 ± 3.89 mmHg·mL; $P = 0.0038$) and cardiac output (CO) (sham vs. hiPS-CM: 13.7 ± 6.4 vs. 29.3 ± 17.2 ; $P = 0.0039$) were significantly higher in the hiPS-CM group (Fig. 2b). A typical example of a pressure–volume loop for each group is shown in Fig. 2a. In the pressure–volume loop analysis, the end-diastolic pressure–volume relation (sham vs. hiPS-CM: 19.9 ± 7.2 vs. 10.9 ± 5.6 /mL; $P < 0.001$), one of the best parameters reflecting diastolic function, was significantly lower in the hiPS-CM group (Fig. 2b). The end-systolic pressure–volume relation (sham vs. hiPS-CM: 1612 ± 637 vs. 1449 ± 544 mmHg/mL; $P = 0.43$) and preload recruitable stroke work (sham vs. c: 60.9 ± 20.5 vs. 59.0 ± 17.9 mmHg; $P = 0.78$), the best indicators of systolic function, were not significantly different between groups (Fig. 2b).

hiPS-CM patch transplantation improved mechanical efficiency

Using positron emission tomography with ^{11}C -acetate, kmono (sham vs. hiPS-CM: 0.31 ± 0.04 vs. 0.29 ± 0.03 /min; $P = 0.28$) and myocardial blood flow (sham vs. hiPS-CM: 4.78 ± 0.77 vs. 4.65 ± 0.50 mL/min/g; $P = 0.75$) did not significantly differ between groups (Fig. 3a–c). However, the cardiac efficiency (CE) approached significance (sham vs. hiPS-CM: 2130 ± 556 vs. 4692 ± 2115 mmHg·mL/m 2 ; $P = 0.052$; Fig. 3d), suggesting a difference in correlation.

Attenuation of RV hypertrophy due to angiogenesis and suppression of myocardial fibrosis after hiPS-CM patch transplantation


Hematoxylin and eosin staining showed that the RV weight and RV hypertrophy decreased more in the hiPS-CM group than in the sham group (Fig. S2). According to the periodic acid-Schiff staining, the diameter of RV cardiomyocytes was significantly smaller in the hiPS-CM group than in the sham group (control vs. sham vs. hiPS-CM: 12.2 ± 0.98 vs. 28.9 ± 1.4 vs. 25.5 ± 2.4 ; all $P < 0.001$; Fig. 4a). Picrosirius red staining showed significantly more interstitial fibrosis within the RV myocardium in the sham and hiPS-CM groups than in the control group (control vs. sham vs. hiPS-CM: $5.4 \pm 1.9\%$ vs. $30.4 \pm 3.1\%$ vs. $22.6 \pm 3.8\%$; $P < 0.001$ for sham and hiPS-CM vs. control; Fig. 4b). However, the myocardial RV fibrosis percentage was significantly lower in the hiPS-CM group than in the sham group ($P < 0.001$). Furthermore, the myocardial capillary density, assessed by vWF staining, was significantly higher in the hiPS-CM group than in the sham group (control vs. sham vs. hiPS-CM: 821 ± 90 vs. 411 ± 68 vs. 647 ± 121 units/mm 2 ; $P = 0.003$ for sham vs. hiPS-CM; Fig. 4c). RV capillary density and myocardial fibrosis were inversely correlated (Fig. 4d).

hiPS-CM engraftment after transplantation

We investigated the degree of hiPS-CM engraftment using immunolabeled Sects. 1, 2, and 4 weeks after hiPS-CM patch transplantation ($n = 4$ each). hiPS-CMs were detected in the RV myocardium of rats even 4 weeks after transplantation, although there were clear reductions in levels compared with those observed at 1 and 2 weeks after hiPS-CM patch transplantation (Fig. 5).

Upregulation of angiogenic cytokine expression after hiPS-CM patch transplantation

The expression of *vascular endothelial growth factor* (VEGF) (sham vs. hiPS-CM(4w): 0.74 ± 0.18 vs. 1.01 ± 0.27 ; $P = 0.02$) and *platelet-derived growth factor* (PDGF) (sham

 Springer

vs. hiPS-CM(4w): 2.09 ± 0.76 vs. 2.72 ± 0.69 ; $P=0.04$) was significantly higher in the hiPS-CM(4w) group than in the sham group (sham, $n=18$; hiPS-CM(4w), $n=15$; Fig. 6). The expression of *insulin-like growth factor 1 (IGF-1)* (sham vs. hiPS-CM(4w) vs. hiPS-CM(2w): 2.34 ± 1.00 vs. 2.81 ± 1.02 vs. 4.58 ± 1.81 ; sham vs. hiPS-CM(4w), $P=0.47$; sham vs. hiPS-CM(2w), $P<0.001$; hiPS-CM(4w) vs. hiPS-CM(2w), $P=0.009$) and *stromal cell-derived factor 1 (SDF-1)* (sham vs. hiPS-CM(4w) vs. iPS-CM (2w): 2.49 ± 0.60 vs. 3.07 ± 0.91 vs. 4.80 ± 1.09 ; sham vs. hiPS-CM(4w), $P=0.11$ sham vs. hiPS-CM(2w), $P<0.001$; hiPS-CM(4w) vs. hiPS-CM(2w), $P<0.001$) was significantly higher in the hiPS-CM(2w) group than in the sham group, but no significant differences were noted between the sham and hiPS-CM(4w) groups. Further, no significant difference was noted in the expression of *hepatocyte growth factor (HGF)* between any groups (sham vs. hiPS-CM(4w) vs. iPS-CM (2w): 3.31 ± 1.44 vs. 4.46 ± 1.65 vs. 4.98 ± 1.94 ; sham vs. hiPS-CM(4w), $P=0.1$; sham vs. hiPS-CM(2w), $P=0.08$; hiPS-CM(4w) vs. hiPS-CM(2w), $P=0.79$). However, the expression of all angiogenic factors was higher in the hiPS-CM(2w) group than in the hiPS-CM(4w) group.

Discussion

This study demonstrated that hiPS-CM improves RV function in the RV pressure-overloaded rat model by promoting angiogenesis in the RV myocardium and suppressing myocardial fibrosis. The main findings are as follows: (1) Diastolic function was significantly improved; (2) fibrosis of the RV myocardium was suppressed, and the capillary density of the RV myocardium increased; and (3) the expression of angiogenesis-related factors was significantly increased. hiPS-CM transplantation has exhibited therapeutic efficacy in studies using left ventricular heart failure models [12, 15, 16]. The present study is the first to show the efficacy of hiPS-CMs for RV dysfunction caused by chronic pressure overload.

The pressure-overloaded RV first adapts by increasing its contractility by enhancing its intrinsic contractile properties and muscle hypertrophy to maintain CO [17, 18]. However, long-term pressure overload results in RV dilatation instead of hypertrophy. Subsequently, RV diastolic function gradually deteriorates, and systolic function is impaired, resulting in decompensated RV failure [18–21]. RV ischemia and fibrosis underly decompensated RV failure.

Capillary rarefaction occurs during the transition from RV hypertrophy to RV failure [22, 23]. In the pressure-overloaded RV model, right coronary artery flow is reduced by a systolic gradient (aortic systolic pressure–RV

systolic pressure) and a decrease in the right coronary diastolic perfusion pressure (aortic diastolic pressure–RV diastolic pressure) [24]. This leads to a loss of RV capillaries (i.e., a decrease in capillary density), which accelerates RV dysfunction. In this study, capillary density was significantly lower in the sham group than in the control group, whereas it was significantly higher in the hiPS-CM group than in the sham group. This suggests that RV myocardium microcapillaries can be maintained or increased by promoting angiogenesis after hiPS-CM patch transplantation and that RV dysfunction can be changed. Increases in angiogenesis-related gene expression, such as *VEGF* and *SDF-1*, were observed in the myocardium 4 weeks after patch transplantation. Herein, xenotransplantation was performed, and it is unclear whether hiPS-CM-expressed angiogenic factors acted directly on the RV myocardium of rats. However, cell transplantation can upregulate various cardioprotective factors via “crosstalk” between transplanted cells and host cardiac tissues [25]. Therefore, hiPS-CM transplantation likely caused the increases in *VEGF* and *HGF* expression in the rats’ myocardium.

RV pressure overload initially increases high-pressure tolerance and enhances collagen formation to maintain the RV shape; however, accumulation of myocardial collagen causes maladaptive changes in the collagen network structure and extracellular matrix integrity, resulting in fibrotic tissue replacing lost cardiomyocytes. This study showed that the antifibrotic cytokine *HGF* was highly expressed in the hiPS-CM group, suggesting that fibrosis progression may have been suppressed. Ischemia also triggers the development of fibrosis in the pressure-overloaded heart as part of a reparative response [26]. This may further enhance susceptibility to chronic ischemia due to a reduced coronary flow reserve and impaired diastolic coronary flow [24]. Similarly, RV fibrosis and capillary density were correlated, suggesting that angiogenesis induced by hiPS-CM transplantation improved myocardial ischemia, suppressed fibrosis, and prevented the exacerbation of RV functional impairment.

Herein, residual cardiomyocytes were confirmed even 4 weeks after hiPS-CM patch transplantation. Considering the number of residual cells, we speculate that hiPS-CMs did not directly contribute to improving RV contractility. The effects may largely depend on paracrine signaling, causing cytokine-induced angiogenesis and antifibrosis.

There were no major differences in the cytokines released by iPS-CMs and skeletal myoblasts in our previous report [15] that demonstrated that hearts transplanted with iPS-CMs showed increased vasculogenesis and decreased apoptosis compared to other cell types. The reason for this disparity remains unclear; however, this study showed that high levels of





Fig. 3 Measurement of in vivo myocardial oxidative metabolism based on the ^{11}C -acetate clearance rate (sham, $n=5$; hiPS-CM, $n=5$). **a** Representative images of myocardial time-activity curves (upper panels) and the polar maps (lower panels) in the sham and human induced pluripotent stem cell-derived cardiomyocyte (hiPS-CM) patch transplantation groups. Kmono was calculated by mono-exponential fitting. **b** The acetate clearance rate (kmono) as a measure of right ventricular (RV) oxygen consumption. **c** Comparison of myocardial blood flow (MBF) in the RV. Kmono and MBF did not significantly differ between the sham and hiPS-CM groups. **d** The hiPS-CM group showed higher cardiac efficacy than the sham group. n.s., non-significant

angiopoietin families that significantly contribute to the maturation of blood were detected in hiPS-CM culture supernatants (Fig. S1d). This may be one of the factors leading to increased angiogenesis in iPS-CMs than in skeletal myoblasts; however, further studies are needed to investigate this.

Cardiac catheterization is more reliable than echocardiography because obtaining accurate measurements during echocardiography in rats is difficult, and load-independent indicators can be measured during catheterization [27]. We previously reported that left ventricular systolic recovery may depend on

angiogenesis via the paracrine effect with myocardial blood flow in the peri-infarct zone in a porcine ischemic cardiomyopathy model due to the ligation of the left anterior-descending coronary artery [12, 15, 16]. In this study, the paracrine effect also improved the overall RV ischemia, suppressed fibrosis, and improved RV diastolic dysfunction. Notably, this study did not provide strong evidence that hiPS-CMs ameliorated systolic/diastolic dysfunction in pressure-overloaded RVs. However, CE was higher in the hiPS-CM group than in the sham group. CE can decline due to tricuspid regurgitation, septal bowing [28], asynchronous activation, and diastolic dysfunction [29]. Therefore, the improvement in diastolic dysfunction may have contributed to the observed increase in CE.

The ideal outcome is for the hiPSC-CM patch to contract/relax synchronously within the recipient heart and contribute to improving cardiac function [30]. However, successful regenerative therapy using hiPS-CMs requires better engraftment of hiPS-CMs within the recipient myocardium for an extended period to enhance the therapeutic efficacy. This can be achieved by immunosuppression [31], promoting angiogenesis using hiPS-CM patch transplantation with an omentum




Fig. 4 Histological assessment of hypertrophy, capillary density, and fibrosis in the right ventricle. **a** The left panels display representative images of periodic acid-Schiff-stained sections in each group. Scale bars: 50 μm. The right graph shows the size of cardiomyocytes in each group. **b** The left panels display representative images of myocardial fibrosis in each group, as assessed by Picrosirius Red staining. Scale bars: 50 μm. The right graph shows the percentage of myocar-

dial fibrosis in each group. **c** The left panels display representative images of immunohistochemistry, assessed using the von Willebrand factor, in each group. Scale bars: 50 μm. The right graph shows the capillary density per unit area. **d** Capillary density was inversely correlated with the percentage of myocardial fibrosis in the right ventricle. * $P < 0.05$




Fig. 5 Serial changes after the engraftment of hiPS-CMs. Sections of the right ventricular myocardium 1, 2, and 4 weeks after hiPS-CM patch transplantation were immunolabeled with the anti-troponin T

antibody, which reacted specifically with human troponin T (hTnT; green). Nuclei were stained with Hoechst 33,258 (blue). hiPS-CM, human induced pluripotent stem cell-derived cardiomyocyte

flap [16, 32], and using suitable myocardial tissue with appropriate cardiomyocyte maturity [33] and orientation [34]. Although we did not use immunosuppressants because this study was conducted on nude rats, the engraftment of hiPS-CMs decreased considerably after 2 months. Future studies should examine the extent of the mechanical contribution of the transplanted cardiomyocytes to the contractile force of the diseased heart.

Limitations

In this study, it was difficult to detect serial changes in RV function during cardiac catheterization because it is invasive in small animals. However, the expression of angiogenesis-related factors was significantly higher at 2 weeks than at 4 weeks after patch transplantation, suggesting that hiPS-CMs may ameliorate RV function more at 2 weeks than at 4 weeks. Further studies with large animals are required to assess this.




Fig. 6 Quantitative polymerase chain reaction analysis of angiogenic cytokine-related gene expression in the right ventricular myocardium. * $P < 0.05$; n.s. Non-significant, VEGF Vascular endothelial growth

factor, IGF-1 Insulin-like growth factor 1, HGF Hepatocyte growth factor, SDF-1 Stromal cell-derived factor 1, PDGF Platelet-derived growth factor

Conclusion

HiPS-CMs attenuated RV diastolic dysfunction in pressure-overloaded RV rats, primarily due to angiogenesis promotion in the myocardium and myocardial fibrosis suppression.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10047-024-01479-3>.

Acknowledgements We would like to thank Kenji Oyama for preparing the hiPS-CM patches; Kenta Kurimoto for preparing the ^{11}C -acetate; Yuwei Liu for the assistance and analysis of the PET results; Takashi Munegaki and Yuka Fujii for the assistance and analysis of the cardiac catheterization results; and Emiko Ito, Maki Takeda, and Kaori Ikuma for their excellent technical assistance. Funding for this research project was provided by JSPS KAKENHI (Grant Number JP19K18183). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions Conceptualization: Takuji Watanabe, Shigeru Miyagawa, Takuji Kawamura, Data curation: Takuji Watanabe, Shigeru Miyagawa, Takuji Kawamura, Akima Harada, Tadashi Watabe, Formal analysis: Takuji Watanabe, Shigeru Miyagawa, Takuji Kawamura, Akima Harada, Tadashi Watabe, Funding acquisition: Shigeru Miyagawa, Takuji Kawamura, Investigation: Takuji Watanabe, Akima Harada, Tadashi Watabe, Methodology: Takuji Watanabe, Shigeru Miyagawa, Takuji Kawamura, Akima Harada, Tadashi Watabe, Eku Shimosegawa, Project administration: Shigeru Miyagawa, Takuji Kawamura, Resources: Shigeru Miyagawa, Takuji Kawamura, Akima Harada, Tadashi Watabe, Software: Takuji Watanabe, Akima Harada, Tadashi Watabe, Supervision: Shigeru Miyagawa, Takuji Kawamura, Tadashi Watabe, Eku Shimosegawa, Masaki Taira, Daisuke Yoshioka, Kazuo Shimamura, Takayoshi Ueno, Validation: Shigeru Miyagawa, Takuji Kawamura, Akima Harada, Tadashi Watabe, Eku Shimosegawa,

Visualization: Takuji Watanabe, Akima Harada, Tadashi Watabe, Writing – original draft: Takuji Watanabe, Takuji Kawamura, Writing – review & editing: Takuji Watanabe, Shigeru Miyagawa, Takuji Kawamura.

Funding Open Access funding provided by Osaka University.

Data availability All relevant data are included within the manuscript and the Supporting Information files.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. *Circulation*. 2007;115:163–72.

2. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. *N Engl J Med*. 1993;329:593–9.
3. Lee C, Lee CH, Kwak JG, Kim SH, Shim WS, Lee SY, et al. Factors associated with right ventricular dilatation and dysfunction in patients with chronic pulmonary regurgitation after repair of tetralogy of Fallot: analysis of magnetic resonance imaging data from 218 patients. *J Thorac Cardiovasc Surg*. 2014;148:2589–95.
4. Lopez L, Cohen MS, Anderson RH, Redington AN, Nykanen DG, Penny DJ, et al. Unnatural history of the right ventricle in patients with congenitally malformed hearts. *Cardiol Young*. 2010;20(Suppl 3):107–12.
5. Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. *Circulation*. 2016;133:770–801.
6. Walker LA, Buttrick PM. The right ventricle: biologic insights and response to disease: updated. *Curr Cardiol Rev*. 2013;9:73–81.
7. Greyson CR. Pathophysiology of right ventricular failure. *Crit Care Med*. 2008;36:S57–65.
8. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N, Matsuda H. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. *Circulation*. 2002;105:2556–61.
9. Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. *J Mol Cell Cardiol*. 2011;50:327–32.
10. Okano T, Yamada N, Sakai H, Sakurai Y. A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide). *J Biomed Mater Res*. 1993;27:1243–51.
11. Miyagawa S, Sawa Y, Sakakida S, Taketani S, Kondoh H, Memon IA, et al. Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium: their integration with recipient myocardium. *Transplantation*. 2005;80:1586–95.
12. Kawamura M, Miyagawa S, Miki K, Saito A, Fukushima S, Higuchi T, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. *Circulation*. 2012;126:S29–37.
13. LekanneDeprez RH, van den Hoff MJ, de Boer PA, Ruijter PM, Maas AA, Chamuleau RA, et al. Changing patterns of gene expression in the pulmonary trunk-banded rat heart. *J Mol Cell Cardiol*. 1998;30:1877–88.
14. Hoashi T, Matsumiya G, Miyagawa S, Ichikawa H, Ueno T, Ono M, et al. Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart. *J Thorac Cardiovasc Surg*. 2009;138:460–7.
15. Ishida M, Miyagawa S, Saito A, Fukushima S, Harada A, Ito E, et al. Transplantation of human-induced pluripotent stem cell-derived cardiomyocytes is superior to somatic stem cell therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction. *Transplantation*. 2019;103:291–8.
16. Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Funakoshi S, et al. Enhanced therapeutic effects of human iPS cell derived-cardiomyocyte by combined cell-sheets with omental flap technique in porcine ischemic cardiomyopathy model. *Sci Rep*. 2017;7:8824.
17. Trip P, Rain S, Handoko ML, van der Bruggen CE, Bogaard HJ, Marcus JT, et al. Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension. *Eur Respir J*. 2015;45:1603–12.
18. Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. *J Am Coll Cardiol*. 2017;69:236–43.
19. Rain S, Handoko ML, Vonk Noordegraaf A, Bogaard HJ, van der Velden J, de Man FS. Pressure-overload-induced right heart failure. *Pflugers Arch*. 2014;466:1055–63.
20. Hein S, Arnon E, Kostin S, Schönborg M, Elsässer A, Polyakova V, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. *Circulation*. 2003;107:984–91.
21. van der Bruggen CEE, Tedford RJ, Handoko ML, van der Velden J, de Man FS. RV pressure overload: from hypertrophy to failure. *Cardiovasc Res*. 2017;113:1423–32.
22. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. *Am J Respir Cell Mol Biol*. 2011;45:1239–47.
23. Ruiter G, Ying Wong Y, de Man FS, Louis Handoko M, Jaspers RT, Postmus PE, et al. Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. *J Heart Lung Transplant*. 2013;32:231–40.
24. van Wolferen SA, Marcus JT, Westerhof N, Spreeuwenberg MD, Marques KM, Bronzwaer JG, et al. Right coronary artery flow impairment in patients with pulmonary hypertension. *Eur Heart J*. 2008;29:120–7.
25. Gonzales C, Pedrazzini T. Progenitor cell therapy for heart disease. *Exp Cell Res*. 2009;315:3077–85.
26. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. *Nat Rev Cardiol*. 2013;10:15–26.
27. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. *Am J Physiol Heart Circ Physiol*. 2005;289:H501–12.
28. Marcus JT, Gan CT, Zwanenburg JJM, Boonstra A, Allaart CP, Götte MJW, Vonk-Noordegraaf A. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. *J Am Coll Cardiol*. 2008;51:750–7.
29. Gan CT-J, Holverda S, Marcus JT, Paulus WJ, Marques KM, Bronzwaer JGF, et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. *Chest*. 2007;132:11–7.
30. Higuchi T, Miyagawa S, Pearson JT, Fukushima S, Saito A, Tsuchimochi H, et al. Functional and electrical integration of induced pluripotent stem cell-derived cardiomyocytes in a myocardial infarction rat heart. *Cell Transplant*. 2015;24:2479–89.
31. Kawamura T, Miyagawa S, Fukushima S, Maeda A, Kashiya N, Kawamura A, et al. Cardiomyocytes derived from MHC-homozygous induced pluripotent stem cells exhibit reduced allogeneic immunogenicity in MHC-matched non-human primates. *Stem Cell Rep*. 2016;6:312–20.
32. Kainuma S, Miyagawa S, Fukushima S, Pearson J, Chen YC, Saito A, et al. Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in failing heart. *Mol Ther*. 2015;23:374–86.
33. Yoshida S, Miyagawa S, Fukushima S, Kawamura T, Kashiya N, Ohashi F, et al. Maturation of human induced pluripotent stem cell-derived cardiomyocytes by soluble factors from human mesenchymal stem cells. *Mol Ther*. 2018;26:2681–95.
34. Li J, Minami I, Shiozaki M, Yu L, Yajima S, Miyagawa S, et al. Human pluripotent stem cell-derived cardiac tissue-like constructs for repairing the infarcted myocardium. *Stem Cell Rep*. 2017;9:1546–59.